Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Kyowa Kirin
Biotech
ASCO: Kura, Kyowa reveal 23% remission rate behind leukemia win
Kura and Kyowa Kirin have shared details of the phase 2 win for ziftomenib as the FDA mulls whether to greenlight the selective menin inhibitor.
James Waldron
Jun 2, 2025 5:36pm
Amgen ignites Rocket program with wins in phase 3 eczema trials
Mar 10, 2025 5:48am
Kura, Kyowa hail ph. 2 win for leukemia drug, but hold back data
Feb 6, 2025 10:40am
Kyowa Kirin fronts $330M to share rights to Kura's leukemia drug
Nov 21, 2024 9:35am
Biogen boosts C-suite with BMS vet—Chutes & Ladders
Nov 1, 2024 8:30am
Boehringer ends week with 3rd deal, this time with Kyowa Kirin
Jan 5, 2024 10:34am
